<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928430</url>
  </required_header>
  <id_info>
    <org_study_id>XT-2002</org_study_id>
    <secondary_id>2020-005979-12</secondary_id>
    <nct_id>NCT04928430</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19</brief_title>
  <official_title>An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenothera SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xenothera SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of XAV-19 drug in patients&#xD;
      with moderate-to-severe COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase II/III, multicenter, international, randomized (1:1), placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of XAV-19 in patients with moderate-to-severe COVID-19.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with an aggravation of COVID-19</measure>
    <time_frame>within 8 days after treatment</time_frame>
    <description>The aggravation is defined as a worsening of the score of at least 1 point on the WHO 7-point ordinal scale compared to the score on the WHO 7-point ordinal scale at randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical parameters : body temperature</measure>
    <time_frame>Between randomization and Day 3, 5, 8 and 15</time_frame>
    <description>°C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical parameters : Respiratory rate</measure>
    <time_frame>Between randomization and Day 3, 5, 8 and 15</time_frame>
    <description>breath/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical parameters : SpO2 at ambiant air</measure>
    <time_frame>Between randomization and Day 3, 5, 8 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical parameters : Supplemental O2</measure>
    <time_frame>Between randomization and Day 3, 5, 8 and 15</time_frame>
    <description>L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in severity on Common Terminology Criteria of Adverse Events (CTCAE) scale (version 5.0)</measure>
    <time_frame>Between randomization and Day 3, 5, 8 and 15</time_frame>
    <description>Shortness of breath and thoracic pain&#xD;
Scale score :&#xD;
Dyspnea: grade 1 (shortness of breath with moderate exertion) to 5 (death) Non-cardiac chest pain: grade 1 (mild pain) to 3 (severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of patient's requirement in supplemental O2</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Time requiring supplemental O2 at Day 15 will be defined as the time in days from randomization to the date of requiring supplemental O2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of aggravation</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Duration of aggravation will be defined as the time in days between start date of aggravation and improvement date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral status: RT-PCR or RT-qPCR for SARS-CoV-2</measure>
    <time_frame>At randomization and on Day 8 or at the end of follow-up, whichever comes first</time_frame>
    <description>(positive/negative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients referred to Intensive Care Unit (ICU)</measure>
    <time_frame>Between randomization and Day 3, 5, 8 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with need for mechanical ventilation</measure>
    <time_frame>At randomization and at Day 3, 5, 8 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rates</measure>
    <time_frame>at day 8 and day 15 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Occurrence of adverse effects</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Number and Proportion of participants with AE, SAE and treatment emergent adverse events leading to study drug discontinuation, to concomitant or additional treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: hypersensitivity or allergy</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Incidence of hypersensitivity reactions and allergy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: laboratories abnormalities : white blood cell count</measure>
    <time_frame>up to 15 days</time_frame>
    <description>G/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: laboratories abnormalities : red blood cell count</measure>
    <time_frame>up to 15 days</time_frame>
    <description>10 12/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: laboratories abnormalities : hemoglobin</measure>
    <time_frame>up to 15 days</time_frame>
    <description>g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: laboratories abnormalities : platelets</measure>
    <time_frame>up to 15 days</time_frame>
    <description>G/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: laboratories abnormalities : creatinine</measure>
    <time_frame>up to 15 days</time_frame>
    <description>µmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">722</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>XAV-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XAV-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XAV-19</intervention_name>
    <description>150 mg of XAV-19 single IV perfusion</description>
    <arm_group_label>XAV-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I1) Male or female patient aged 18 years or over, weighing &gt;50 Kg and &lt;120 Kg, at the time&#xD;
        of signing the informed consent,&#xD;
&#xD;
        I2) Patient presenting in a specialized or an emergency unit&#xD;
&#xD;
        I3) Patient presenting signs of pneumonia evidenced by at least 1 of the following:&#xD;
        auscultation, chest X-Ray, CT scan OR presenting COVID-19 related symptoms having started&#xD;
        less than 10 days prior to screening visit, including at least 2 of the following: fever,&#xD;
        cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain,&#xD;
        headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea&#xD;
&#xD;
        I4) Patient with SpO2 &gt; 90% (at ambient air)&#xD;
&#xD;
        I5) Patient with a first positive SARS-CoV-2 test (RT-PCR, RT-qPCR or antigen test) in the&#xD;
        last 10 days or at screening&#xD;
&#xD;
        I6) Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at&#xD;
        screening and use a highly effective birth control until 90 days after the administration&#xD;
        of study drug&#xD;
&#xD;
        I7) Non-vasectomized male patients having a female partner of childbearing potential must&#xD;
        agree to use a highly effective method of contraception until 90 days after the&#xD;
        administration of study drug,&#xD;
&#xD;
        I8) Patient capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        E1) Patient with a positive SARS CoV-2 test (RT-PCR, RT-qPCR or antigen test) of more than&#xD;
        10 days before the screening visit&#xD;
&#xD;
        E2) Patient with multiorgan failure&#xD;
&#xD;
        E3) Patient requiring immediate Intensive Care Unit (ICU) hospitalization&#xD;
&#xD;
        E4) Patient participating in another clinical trial with an investigative agent&#xD;
&#xD;
        E5) Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernard Vanhove, Dr</last_name>
    <phone>+33(0)255 10 11 73</phone>
    <email>bernard.vanhove@xenothera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot; St. Ekaterina&quot; - Dimitrovgrad - EOOD, COVID Departement</name>
      <address>
        <city>Dimitrovgrad</city>
        <zip>6400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment - Plovdiv - AD, COVID Departement</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Oncological Center - Ruse Ltd, COVID Departement</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment for Pneumophtisiatrics Diseases Dr. Dimitar Gramatikov - Ruse - EOOD, Departement of Pneumology</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>5th Multiprofile hospital for Active Treatment - Sofia - EAD, Departement of Pneumology and Phtisiatric</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelismos General Hospital of Athens, Critical Care Departement</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Sotiria&quot; General Hospital of Chest Diseases of Athens, 3rd Department of Medicine of University of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion, Department of Internal Medicine &amp; Infectious Diseases Unit</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AHEPA University General Hospital of Thessaloniki, Infectious Diseases Division of 1st Internal Medicine Department</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Hippokration&quot; General Hospital of Thessaloniki, 3rd Department of Pediatrics</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leon Daniello Clinical Hospital of Pneumoftiziology</name>
      <address>
        <city>Cluj-napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital for Infectious Diseases and Pneumology &quot;Victor Babeş&quot; Craiova</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Field Hospital ROL-2</name>
      <address>
        <city>Otopeni</city>
        <zip>075100</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pius Brinzeu County Emergency Clinical Hospital Timisoara</name>
      <address>
        <city>Timisoara</city>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ramón y Cajal University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Puerta del Hierro University Hospital</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bağcılar Medipol Mega Universite Hastanesi</name>
      <address>
        <city>Bağcılar</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty</name>
      <address>
        <city>Fatih</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>polyclonal IgG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

